A First In Human Study Of PF-00184562 In Healthy Volunteers

• Status: Completed
• Trial end date: 2005-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purposes of this study are:

• To determine the safety, tolerability and pharmacokinetics of single doses of PF-00184562; and

• To explore the exposure-response relationship of neuropsychometric and tolerability measures of PF-00184562 compared to olanzapine.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pfizer
• Collaborator: PPD
• Treatments: Olanzapine

Criteria

Inclusion Criteria:

• Healthy male or female subjects of non-childbearing potential

Exclusion Criteria:

• Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, pancreatic, psychiatric, neurologic, active infections, immunological, or allergic disease (including drug allergies and seasonal allergies at time of dosing).